Online inquiry

IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8052MR)

This product GTTS-WQ8052MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8052MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8567MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ4352MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ9153MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ11420MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ3404MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ11804MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ7473MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ6781MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW